12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Company News  |  Deals

Inovio, PATH deal

PATH's PATH Malaria Vaccine Initiative (MVI) will provide undisclosed funding for non-human primate studies of Inovio's SynCon DNA malaria vaccine. The synthetic DNA...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >